| pubmed-article:10337009 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:10337009 | lifeskim:mentions | umls-concept:C0025936 | lld:lifeskim |
| pubmed-article:10337009 | lifeskim:mentions | umls-concept:C0019733 | lld:lifeskim |
| pubmed-article:10337009 | lifeskim:mentions | umls-concept:C0039195 | lld:lifeskim |
| pubmed-article:10337009 | lifeskim:mentions | umls-concept:C0033684 | lld:lifeskim |
| pubmed-article:10337009 | lifeskim:mentions | umls-concept:C0026882 | lld:lifeskim |
| pubmed-article:10337009 | lifeskim:mentions | umls-concept:C0920679 | lld:lifeskim |
| pubmed-article:10337009 | lifeskim:mentions | umls-concept:C0205369 | lld:lifeskim |
| pubmed-article:10337009 | lifeskim:mentions | umls-concept:C0205263 | lld:lifeskim |
| pubmed-article:10337009 | pubmed:issue | 2 | lld:pubmed |
| pubmed-article:10337009 | pubmed:dateCreated | 1999-6-3 | lld:pubmed |
| pubmed-article:10337009 | pubmed:abstractText | Cytotoxic T cells (CTL) recognize short peptides that are derived from the proteolysis of endogenous cellular proteins and presented on the cell surface as a complex with MHC class I molecules. CTL can recognize single amino acid substitutions in proteins, including those involved in malignant transformation. The mutated sequence of an oncogene may be presented on the cell surface as a peptide, and thus represents a potential target antigen for tumour therapy. The p21ras gene is mutated in a wide variety of tumours and since the transforming mutations result in amino acid substitutions at positions 12, 13 and 61 of the protein, a limited number of ras peptides could potentially be used in the treatment of a wide variety of malignancies. A common substitution is Val for Gly at position 12 of p21ras. In this study, we show that the peptide sequence from position 5 to position 14 with Val at position 12-ras p5-14 (Val-12)-has a motif which allows it to bind to HLA-A2.1. HLA-A2.1-restricted ras p5-14 (Val-12)-specific CTL were induced in mice transgenic for both HLA-A2.1 and human beta2-microglobulin after in vivo priming with the peptide. The murine CTL could recognize the ras p5-14 (Val-12) peptide when they were presented on both murine and human target cells bearing HLA-A2.1. No cross-reactivity was observed with the native peptide ras p5-14 (Gly-12), and this peptide was not immunogenic in HLA-A2.1 transgenic mice. This represents an interesting model for the study of an HLA-restricted CD8 cytotoxic T cell response to a defined tumour antigen in vivo. | lld:pubmed |
| pubmed-article:10337009 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10337009 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10337009 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10337009 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10337009 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10337009 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10337009 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10337009 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10337009 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10337009 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10337009 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10337009 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10337009 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10337009 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10337009 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10337009 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10337009 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10337009 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10337009 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10337009 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10337009 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10337009 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10337009 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10337009 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10337009 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10337009 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10337009 | pubmed:language | eng | lld:pubmed |
| pubmed-article:10337009 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10337009 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:10337009 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10337009 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10337009 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10337009 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10337009 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:10337009 | pubmed:month | May | lld:pubmed |
| pubmed-article:10337009 | pubmed:issn | 0009-9104 | lld:pubmed |
| pubmed-article:10337009 | pubmed:author | pubmed-author:MachJ PJP | lld:pubmed |
| pubmed-article:10337009 | pubmed:author | pubmed-author:CorradinGG | lld:pubmed |
| pubmed-article:10337009 | pubmed:author | pubmed-author:HolmerMM | lld:pubmed |
| pubmed-article:10337009 | pubmed:author | pubmed-author:YuZZ | lld:pubmed |
| pubmed-article:10337009 | pubmed:author | pubmed-author:EscobarPP | lld:pubmed |
| pubmed-article:10337009 | pubmed:author | pubmed-author:TerskikhAA | lld:pubmed |
| pubmed-article:10337009 | pubmed:author | pubmed-author:HealyFF | lld:pubmed |
| pubmed-article:10337009 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:10337009 | pubmed:volume | 116 | lld:pubmed |
| pubmed-article:10337009 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:10337009 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:10337009 | pubmed:pagination | 214-9 | lld:pubmed |
| pubmed-article:10337009 | pubmed:dateRevised | 2009-11-18 | lld:pubmed |
| pubmed-article:10337009 | pubmed:meshHeading | pubmed-meshheading:10337009... | lld:pubmed |
| pubmed-article:10337009 | pubmed:meshHeading | pubmed-meshheading:10337009... | lld:pubmed |
| pubmed-article:10337009 | pubmed:meshHeading | pubmed-meshheading:10337009... | lld:pubmed |
| pubmed-article:10337009 | pubmed:meshHeading | pubmed-meshheading:10337009... | lld:pubmed |
| pubmed-article:10337009 | pubmed:meshHeading | pubmed-meshheading:10337009... | lld:pubmed |
| pubmed-article:10337009 | pubmed:meshHeading | pubmed-meshheading:10337009... | lld:pubmed |
| pubmed-article:10337009 | pubmed:meshHeading | pubmed-meshheading:10337009... | lld:pubmed |
| pubmed-article:10337009 | pubmed:meshHeading | pubmed-meshheading:10337009... | lld:pubmed |
| pubmed-article:10337009 | pubmed:meshHeading | pubmed-meshheading:10337009... | lld:pubmed |
| pubmed-article:10337009 | pubmed:meshHeading | pubmed-meshheading:10337009... | lld:pubmed |
| pubmed-article:10337009 | pubmed:meshHeading | pubmed-meshheading:10337009... | lld:pubmed |
| pubmed-article:10337009 | pubmed:meshHeading | pubmed-meshheading:10337009... | lld:pubmed |
| pubmed-article:10337009 | pubmed:meshHeading | pubmed-meshheading:10337009... | lld:pubmed |
| pubmed-article:10337009 | pubmed:meshHeading | pubmed-meshheading:10337009... | lld:pubmed |
| pubmed-article:10337009 | pubmed:meshHeading | pubmed-meshheading:10337009... | lld:pubmed |
| pubmed-article:10337009 | pubmed:meshHeading | pubmed-meshheading:10337009... | lld:pubmed |
| pubmed-article:10337009 | pubmed:year | 1999 | lld:pubmed |
| pubmed-article:10337009 | pubmed:articleTitle | Induction in transgenic mice of HLA-A2.1-restricted cytotoxic T cells specific for a peptide sequence from a mutated p21ras protein. | lld:pubmed |
| pubmed-article:10337009 | pubmed:affiliation | Institute of Biochemistry and Swiss Institute for Experimental Cancer Research, University of Lausanne, Epalinges, Switzerland. | lld:pubmed |
| pubmed-article:10337009 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:10337009 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
